Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

CD16, CD57 and DNAM-1 Positive NK Cells Predict MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Bortezomib, Thalidomide and Dexamethasone

Charlotte L.B.M. Korst, Carolien Duetz, Wassilis S.C Bruins, A. Vera de Jonge, Kaz Groen, Christie P.M. Verkleij, Kristine A. Frerichs, Meliha Cosovic, Inoka Twickler, Rosa Rentenaar, Merve Eken, Paola Homan-Weert, Philippe Moreau, Pieter Sonneveld, Sonja Zweegman, Tuna Mutis, Niels W.C.J. Van De Donk

Blood (2023) 142 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2023-177560

Published: 2023

Journal Articles

Baseline CD57 + and CD16 + NK-Cells Predict Treatment Outcome in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Ixazomib-Dexamethasone

Wassilis S.C Bruins, Carolien Duetz, Kaz Groen, Charlotte L.B.M. Korst, A.Vera de Jonge, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Paola Homan-Weert, Christie P.M. Verkleij, Kristine A. Frerichs, Niels WCJ van de Donk, Sonja Zweegman, Tuna Mutis

Blood (2023) 142 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2023-189527

Published: 2023

Journal Articles

Dual Split-Signaling TIM3+CLEC12a Targeting CAR T-Cells with Optimized Signaling As a Safe Potential Therapy for Acute Myeloid Leukemia

Jort J Van Der Schans, Paresh Vishwasrao, Noortje Van Gils, Mashhour Hosny, Ziyu Wang, Jennemiek Van Arkel, Sonja Zweegman, Maria Themeli, Gert Ossenkoppele, Niels W.C.J. van de Donk, Arjan A. Van de Loosdrecht, Linda Smit, Tuna Mutis

Blood (2023) 142 (Supplement 1): 883.

https://doi.org/10.1182/blood-2023-180799

Published: 2023

Journal Articles

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

A. Vera de Jonge, Carolien Duetz, Wassilis S.C Bruins, Charlotte L.B.M. Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Marcel Nijland, Marjolein Van Der Poel, Koen de Heer, Clara Klerk, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry R. Koene, Erik van Werkhoven, Martine E.D. Chamuleau, Tuna Mutis

Blood (2023) 142 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2023-180734

Published: 2023

Journal Articles

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

A.Vera de Jonge, Carolien Duetz, Wassilis S.C. Bruins, Erik D. van Werkhoven, Marcel Nijland, Marjolein W.M. Van Der Poel, Koen de Heer, Clara P.W. Klerk, Yorick Sandberg, Rob Fijnheer, Pim Mutseaers, Djamila E. Issa, Lara H. Böhmer, Roel J.W. Van Kampen, Otto J. Visser, Daphne de Jong, Josée M. Zijlstra, Tuna Mutis, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 9298–9299.

https://doi.org/10.1182/blood-2022-163068

Published: 2022

Journal Articles

Modakafusp Alfa (TAK-573), a Novel CD38-Targeting Attenuated Interferon-Alpha Immunocytokine, Kills MM Cells Via NK Cell Activation

Wassilis S.C. Bruins, Rosa Rentenaar, Sabrina Collins, James F. Sampson, Niels WCJ Van De Donk, Sonja Zweegman, Tuna Mutis

Blood (2022) 140 (Supplement 1): 4236–4237.

https://doi.org/10.1182/blood-2022-156387

Published: 2022

Journal Articles

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma

Charlotte L.B.M. Korst, Wassilis S.C. Bruins, Meliha Cosovic, Christie P.M. Verkleij, Inoka Twickler, Diane Le Clerre, Isabelle Chion-Sotinel, Sonja Zweegman, Roman Galetto, Tuna Mutis, Niels WCJ Van De Donk

Blood (2022) 140 (Supplement 1): 4215–4216.

https://doi.org/10.1182/blood-2022-157950

Published: 2022

Journal Articles

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

A. Vera de Jonge, Erik D. van Werkhoven, Marcel Nijland, Koen de Heer, Marjolein W.M. Van Der Poel, Yorick Sandberg, Clara Klerk, Esther E.E. Drees, Margaretha GM Roemer, Daphne de Jong, D. Michiel Pegtel, Bronno van der Holt, Tuna Mutis, Josée M Zijlstra, Marie José Kersten, Martine E.D Chamuleau

Blood (2021) 138 (Supplement 1): 1414.

https://doi.org/10.1182/blood-2021-146812

Published: 2021

Journal Articles

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Blood (2021) 138 (Supplement 1): 728.

https://doi.org/10.1182/blood-2021-150913

Published: 2021

Journal Articles

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

Christie P.M. Verkleij, MD, Marloes Broekmans, Amy Wong, Sonja Zweegman, MDPhD, Raluca Verona, PhD, Homer Adams, III, PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141187

Published: 2020

Journal Articles

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Wassilis S.C. Bruins, MDMSc, Wenrou Zheng, MSc, Jack P. Higgins, PhD, Erin K. Willert, PhD, John Newcomb, PhD, Ajeeta B Dash, PhD, Niels W.C.J. Van De Donk, MD PhD, Sonja Zweegman, MDPhD, Tuna Mutis, MD PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136928

Published: 2020

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Hilma J Van Der Horst, MSc, A. Vera de Jonge, Ida H Hiemstra, PhD, Anne T Gelderloos, MSc, Daniella RAI Berry, Nathalie J Hijmering, Daphne de Jong, Prof Dr, Martine E.D. Chamuleau, Sonja Zweegman, MD PhD, Esther CW Breij, DPhil, Margaretha GM Roemer, PhD, Tuna Mutis

Blood (2019) 134 (Supplement_1): 4066.

https://doi.org/10.1182/blood-2019-125765

Published: 2019

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study

Kristine A. Frerichs, MD, Monique C. Minnema, Mark-David Levin, MD PhD, Annemiek Broyl, MD PhD, Gerard Bos, MD PhD, Marie José Kersten, MD PhD, Tuna Mutis, Christie P.M. Verkleij, MD, Patricia W.C. Bosman, MSc, Saskia K. Klein, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1826.

https://doi.org/10.1182/blood-2019-123383

Published: 2019

Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 5536.

https://doi.org/10.1182/blood-2019-128605

Published: 2019

Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn

Blood (2019) 134 (Supplement_1): 3106.

https://doi.org/10.1182/blood-2019-125788

Published: 2019

Journal Articles

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Marzia Capelletti, PhD MMSc, Jessica Liegel, MD, Maria Themeli, MD PhD, Tuna Mutis, Dina Stroopinsky, PhD, Shira Orr, PhD, Daniela Torres, Adam Morin, Gertrude Gunset, BA, Haider Ghiasuddin, Maryam Rahimian, MD, Myrna Nahas, MD, Lina Bisharat, Shufen Meng, MD, Nikhil C. Munshi, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, Michel Sadelain, MD PhD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 3227.

https://doi.org/10.1182/blood-2019-124944

Published: 2019

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

NARROW

CD16, CD57 and DNAM-1 Positive NK Cells Predict MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Bortezomib, Thalidomide and Dexamethasone

Baseline CD57 + and CD16 + NK-Cells Predict Treatment Outcome in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Ixazomib-Dexamethasone

Dual Split-Signaling TIM3+CLEC12a Targeting CAR T-Cells with Optimized Signaling As a Safe Potential Therapy for Acute Myeloid Leukemia

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Modakafusp Alfa (TAK-573), a Novel CD38-Targeting Attenuated Interferon-Alpha Immunocytokine, Kills MM Cells Via NK Cell Activation

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only